Haemodynamic Effects of Dobutamine in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
- Conditions
- Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2023-508298-10-00
- Lead Sponsor
- Region Midtjylland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and/or endomyocardial biopsy., Treated with loop diuretics., New York Heart Association (NYHA) class II-IV., Age = 65 years., Left ventricular ejection fraction (LVEF) < 50 % and/or SVI assessed by echocardiography < 35 ml/m2., Informed consent.
Moderate to severe aortic stenosis (patients with aortic sclerosis will not be excluded)., Other significant valvular diseases., Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (< 4 weeks)., Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method